GLAXF GSK plc

NEUTRAL Impact: 3/10 6-K
Horizon immediate Filed Apr 2, 2026 Processed 1mo ago SEC 0001654954-26-003197
Notable filing: 6-K
Latest settled — T+20d ⚠ clustered
GLAXF ▼ -2.69% at T+20d
NEUTRAL call ✗ call lost -2.69% · α vs SPY -12.57% · entry $26.75 → $26.03
Next anchor: T+60d in 6w
Currently $25.70 · -3.93% from $26.75 entry
Entry anchored
Apr 2, 2026
via day open
T+1d
-0.75%
call -0.75% · α -1.22%
$26.55
settled 6w ago
T+5d
+9.35%
call +9.35% · α +5.73%
$29.25
settled 6w ago
T+20d
-2.69%
call -2.69% · α -12.57%
$26.03
settled 19d ago
T+60d
call — · α —
in 6w

Price Chart

Loading chart...

Executive Summary

GSK plc repurchased 345,000 ordinary shares on April 1, 2026, at an average price of 2,106.14 GBp per share, as part of its ongoing buyback program. Since February 17, 2026, the company has bought back 16.57 million shares. This reduces the number of shares outstanding and increases the percentage of shares held in treasury to 6.32%.

Actionable Insight

This is a routine share buyback under a pre-announced program. While buybacks can support the stock price over time by reducing shares outstanding, this single day's activity is not material enough to significantly alter the investment thesis. Monitor the pace of future buybacks and overall capital allocation strategy.

Key Facts

  • GSK repurchased 345,000 ordinary shares on April 1, 2026
  • Average price paid: 2,106.14 GBp per share
  • Lowest price: 2,086.00 GBp, Highest price: 2,122.00 GBp
  • Part of an ongoing buyback program; 16,566,521 shares purchased since February 17, 2026
  • Following the purchase, 256,457,615 shares are held in treasury
  • Percentage of voting rights in treasury shares is now 6.32%

Financial Impact

The company spent approximately £7.27 million (345,000 shares * 2,106.14 GBp) on this repurchase, reducing its cash and increasing treasury stock on the balance sheet.

cashequityshares outstanding

Risk Factors

  • Routine buyback activity does not reflect on the company's underlying operational performance
  • The impact on earnings per share will be minimal given the small number of shares repurchased relative to the total outstanding

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-003197
Document: 0001654954-26-003197-index-headers.html0001654954-26-003197
Document: 0001654954-26-003197-index.html0001654954-26-003197
Document: 0001654954-26-003197.txt0001654954-26-003197
41 reports for GLAXF
Performance horizon
44% Hit rate 4 of 9 directional calls best @ T+5▲ +7.60%Apr 1, 2026
Filters
Rows
Reports for GLAXF — sortable, filterable
Type Now
May 20, 2026
today
6-K
NEUTRAL ★ 2/10
$24.50 awaiting T+5awaiting T+5$25.70 (+4.90%)
May 20, 2026
today
6-K
NEUTRAL ★ 1/10
$24.50 awaiting T+5awaiting T+5$25.70 (+4.90%)
May 18, 2026
2d ago
6-K
BULLISH ★ 6/10
awaiting T+5
May 14, 2026
6d ago
6-K
NEUTRAL ★ 2/10
$24.50 awaiting T+5awaiting T+5$25.70 (+4.90%)
May 11, 2026
9d ago
6-K
NEUTRAL ★ 2/10
$25.47 $25.70▲ +0.90%▲ +0.99%$25.70 (+0.90%)
May 11, 2026
9d ago
6-K
NEUTRAL ★ 4/10
$25.47 $25.70▲ +0.90%▲ +0.99%$25.70 (+0.90%)
May 11, 2026
9d ago
6-K
NEUTRAL ★ 2/10
$25.47 $25.70▲ +0.90%▲ +0.99%$25.70 (+0.90%)
May 6, 2026
14d ago
6-K
NEUTRAL ★ 2/10
$25.26 $25.47▲ +0.83%▼ −0.30%$25.70 (+1.74%)
May 5, 2026
15d ago
6-K
NEUTRAL ★ 2/10
$25.01 $25.47▲ +1.84%▼ −0.15%$25.70 (+2.76%)
May 1, 2026
19d ago
6-K
NEUTRAL ★ 1/10
$27.18 $25.26▼ −7.06%▼ −9.41%$25.70 (−5.45%)
Showing 10 of 41

US Market Status

Market Closed — Opens Thu (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access